Compare Bristol-Myers Squibb Co (BMY) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Hyatt Hotels Corporation — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while Hyatt Hotels Corporation trades at $189.7 (market cap $17.86B). The key difference: Bristol-Myers Squibb Co is far larger — about 6.5× Hyatt Hotels Corporation's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | H | |
|---|---|---|
Market Cap | $116.30B | $17.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $202.09 |
52-Week Low | $42.60 | $135.01 |
Enterprise Value | $152.24B | $21.71B |
Dividend Yield | 4.42% | 0.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Hyatt Hotels (H) trades at $184.72, down 3.36% in the last session, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company reported Q1 2026 EPS of $0.63, beating expectations, but faces profitability challenges with negative net income margins and ROE. Recent developments include expansion announcements and strategic investor presentations, while analyst consensus remains cautiously optimistic with a $198.20 price target.
Hyatt presents a growth opportunity through hotel expansion and premium positioning, but investors face risks from inconsistent profitability, rising debt levels, and economic sensitivity. The stock's valuation appears stretched with a P/E of 31.36, requiring strong execution on revenue growth and margin improvement to justify current levels amid competitive and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
